Loading
Bria-OTS is a set of ready-made cell-based immunotherapies from BriaCell Therapeutics, matched to the patient. It is in an early trial in breast cancer, and prostate cancer is the next planned use.
Bria-OTS is a platform of personalised off-the-shelf cell-based immunotherapies from BriaCell Therapeutics, in a phase 1/2 study initially targeting breast cancer, according to the company, which plans to extend it to prostate cancer. NCI SBIR Phase II grant 5R44CA281555-03 funds BriaCell's work on an off-the-shelf tumour cell vaccine with HLA-matching alleles for advanced metastatic prostate cancer.
Described by BriaCell Therapeutics as a platform of personalised off-the-shelf cell-based immunotherapies; its NCI award describes an off-the-shelf tumour cell vaccine carrying HLA-matching alleles.
1.Bria-OTS slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Bria-OTS" OR ABSTRACT:"Bria-OTS") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Bria-OTS, not a curated reading list.
Shares BriaCell Therapeutics, Off-the-shelf cancer vaccines and the tag pipeline.
Shares BriaCell Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/